B. Metzler seel. Sohn & Co. Holding AG Invests $830,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report) during the third quarter, HoldingsChannel reports. The firm acquired 9,241 shares of the company’s stock, valued at approximately $830,000.

Several other institutional investors have also added to or reduced their stakes in AXSM. Whalen Wealth Management Inc. acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at about $236,000. Royce & Associates LP grew its holdings in shares of Axsome Therapeutics by 73.1% during the third quarter. Royce & Associates LP now owns 22,500 shares of the company’s stock worth $2,022,000 after buying an additional 9,500 shares in the last quarter. WCM Investment Management LLC raised its position in Axsome Therapeutics by 0.3% in the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock valued at $10,191,000 after buying an additional 347 shares during the last quarter. Versor Investments LP bought a new stake in Axsome Therapeutics in the 3rd quarter valued at approximately $791,000. Finally, Privium Fund Management B.V. boosted its position in Axsome Therapeutics by 7.9% during the 3rd quarter. Privium Fund Management B.V. now owns 80,232 shares of the company’s stock worth $7,210,000 after acquiring an additional 5,900 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $98.68 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of -15.11 and a beta of 1.26. Axsome Therapeutics, Inc. has a twelve month low of $60.28 and a twelve month high of $105.00. The company has a 50-day simple moving average of $90.99 and a two-hundred day simple moving average of $85.01.

Axsome Therapeutics (NASDAQ:AXSMGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the previous year, the company posted ($1.32) earnings per share. Analysts forecast that Axsome Therapeutics, Inc. will post -4.75 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on AXSM. HC Wainwright reissued a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, September 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Axsome Therapeutics in a research report on Monday, September 16th. Royal Bank of Canada raised their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a report on Friday, October 4th. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $130.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 12th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $124.93.

Read Our Latest Research Report on Axsome Therapeutics

Insider Activity

In other Axsome Therapeutics news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares of the company’s stock, valued at $913,282.62. This trade represents a 52.41 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

See Also

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSMFree Report).

Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.